U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542379) titled 'The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer' on April 14.
Brief Summary: This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.
Study Start ...